bio

Based on an original dataset, the authors analyze empirically the determinants of firm growth in the French biotech industry during two periods, 1996-1999 and 1999-2002.

The Boyd Company compared the costs of operating a biomedical research and product development facilities within 50 North American and European cities. In determining operating costs, the study included skilled labor, facility lease rates, utilities, corporate travel, and other occupancy factors.

The Boyd Company compared the costs of operating a biomedical research and product development facilities within 50 North American and European cities. In determining operating costs, the study included skilled labor, facility lease rates, utilities, corporate travel, and other occupancy factors.

The annual survey on revenues and the issues they face in commercializing products states that there are over 450 Canadian biotechs in areas such as vaccines, stem cell research and plant biotech. In 2003, $1.9 billion was invested into the Canadian biotech sector, the majority of which went to public companies, leaving $242.4 million for private biotech companies.

The author suggests that Arizona follow the steps of younger regions such as Austin and San Diego to leapfrog ahead of the competition in science and technology in order to become a leader in bioscience.

This study focuses on the Italian biotechnology industry, with particular reference to the way in which innovation is generated and managed in Italian biotechnology companies.

The report provides a quantitative analysis of the Canadian biopharmaceutical sector using the Medline biomedical scientific articles database and the United States Patents and Trademark Office database. It uses stationary distributions (1996-2001) to compare Canada to other countries as well as Canadian provinces, Census Metropolitan Areas and institutions among themselves.

The paper is part of a series of research and policy reports designed to contribute to a greater understanding of the extent, speed and implications of this transformation in the agri-food sector and to provide for a broader public policy debate about the resulting opportunities and challenges both within and around the agri-food industry.

This paper examines the determinants of M&A activity in the pharmaceutical-biotechnology industry and the effects of mergers using propensity scores to control for merger endogeneity. Among large firms, the authors find that mergers are a response to excess capacity due to anticipated patent expirations and gaps in a companys product pipeline.

This paper has been prepared as part of CPDs ongoing agricultural policy research and advocacy activities with IRRI under the PETRRA project. It discusses the benefits and risks of rice biotechnology research and genetically engineered varieties developed from such research. It assesses the potential benefits of biotechnology for rice improvement in the context of Bangladesh.